Sitagliptin noninferior to placebo in cardiovascular outcomes study

Merck announced that the primary endpoint of noninferiority for the composite cardiovascular endpoint had been met in a study that evaluated sitagliptin, an oral dipeptidyl peptidase-4 inhibitor.

The primary endpoint was the time to first confirmed cardiovascular event, which included a composite of cardiovascular-related death, nonfatal MI, nonfatal stroke or unstable angina requiring hospitalization.

The company also said hospitalization for heart failure was similar in patients who received sitagliptin and those who received placebo.

Results of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study are scheduled to be presented at the American Diabetes Association Scientific Sessions on June 8 in Boston.

The FDA already approved sitagliptin for adults with type 2 diabetes. The agency requires pharmaceutical companies to conduct postmarketing studies that examine heart failure.

The TECOS study included 14,724 patients from 38 countries who enrolled between Dec. 2008 and July 2012. All patients had type 2 diabetes, a history of cardiovascular disease and a hemoglobin A1c level between 6.5 percent and 8 percent.

Patients were randomized to receive one 50 mg or 100 mg tablet of sitagliptin once daily or a matching placebo. The mean follow-up was approximately three years.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup